Supernus Pharmaceuticals (SUPN) Stock Price Up 5.2%

Share on StockTwits

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) shares rose 5.2% during mid-day trading on Friday . The stock traded as high as $48.28 and last traded at $48.20. Approximately 902,003 shares were traded during trading, an increase of 20% from the average daily volume of 753,066 shares. The stock had previously closed at $45.80.

SUPN has been the topic of several analyst reports. Piper Jaffray Companies set a $47.00 target price on Supernus Pharmaceuticals and gave the company a “hold” rating in a research report on Sunday, July 8th. BidaskClub cut Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 24th. Zacks Investment Research cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 1st. ValuEngine raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 12th. Finally, Cantor Fitzgerald set a $56.00 target price on Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $54.09.

The firm has a market capitalization of $2.37 billion, a P/E ratio of 36.90 and a beta of 0.83. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.74 and a quick ratio of 2.54.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.14. The business had revenue of $99.54 million for the quarter, compared to analyst estimates of $101.01 million. Supernus Pharmaceuticals had a return on equity of 30.57% and a net margin of 24.17%. equities analysts expect that Supernus Pharmaceuticals Inc will post 1.98 EPS for the current fiscal year.

In related news, CFO Gregory S. Patrick sold 35,000 shares of Supernus Pharmaceuticals stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $56.63, for a total transaction of $1,982,050.00. Following the sale, the chief financial officer now directly owns 75,975 shares in the company, valued at $4,302,464.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 7,205 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, June 21st. The stock was sold at an average price of $60.00, for a total value of $432,300.00. Following the sale, the vice president now owns 14,705 shares in the company, valued at $882,300. The disclosure for this sale can be found here. Insiders have sold 110,000 shares of company stock worth $6,144,826 over the last quarter. 6.20% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of Supernus Pharmaceuticals by 8.7% in the second quarter. BlackRock Inc. now owns 7,690,669 shares of the specialty pharmaceutical company’s stock valued at $460,287,000 after buying an additional 618,722 shares during the period. Summit Trail Advisors LLC raised its stake in shares of Supernus Pharmaceuticals by 4,144.2% in the first quarter. Summit Trail Advisors LLC now owns 1,617,365 shares of the specialty pharmaceutical company’s stock valued at $1,617,000 after buying an additional 1,579,257 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Supernus Pharmaceuticals by 0.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,403,994 shares of the specialty pharmaceutical company’s stock valued at $64,303,000 after buying an additional 4,844 shares during the period. Champlain Investment Partners LLC raised its stake in shares of Supernus Pharmaceuticals by 5.1% in the first quarter. Champlain Investment Partners LLC now owns 1,275,155 shares of the specialty pharmaceutical company’s stock valued at $58,402,000 after buying an additional 62,370 shares during the period. Finally, Wells Fargo & Company MN raised its stake in shares of Supernus Pharmaceuticals by 6.8% in the second quarter. Wells Fargo & Company MN now owns 957,210 shares of the specialty pharmaceutical company’s stock valued at $57,290,000 after buying an additional 61,100 shares during the period. Institutional investors and hedge funds own 97.42% of the company’s stock.

Supernus Pharmaceuticals Company Profile (NASDAQ:SUPN)

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Further Reading: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply